NF-κB

Scientific explanation

NF-κB factors link inflammatory cytokines and innate sensors to survival, production and sometimes therapy resistance.

Cancers where relevant

Mesothelioma Gastric cancer Esophageal cancer Hepatocellular carcinoma Liver cancer Cervical cancer Bladder cancer Hodgkin lymphoma Non-Hodgkin lymphoma Multiple myeloma Head and neck cancers

Compounds that intersect this pathway

Disulfiram

ALDH ; copper-complexed forms can inhibit proteasome and NF-κB-related survival programmes in models. Clinical oncology evidence remains limited.

Evidence in mapped cancers: In Vitro · In Vivo · Early Clinical

Curcumin

Polyphenol with promiscuous in-vitro NF-κB, and ROS effects. Bioavailability is poor; dish activity does not establish clinical anticancer efficacy.

Evidence in mapped cancers: In Vitro · Mechanistically Plausible

Resveratrol

Stilbene with sirtuin/-related and anti-inflammatory reports in models. Pharmacokinetic limits and mixed trials caution against efficacy claims.

Convergence partners

Other pathways that co-occur with NF-κB on mapped adjunct records: JAK/STAT, Cancer stemness, Oxidative stress.

This oncology atlas is educational. Pathway maps, adjunctive strategies, and compound listings describe mechanistic relevance. They do not establish clinical efficacy, do not recommend treatment, and are not a substitute for oncology care. Evidence tiers are not equivalent.